Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial-Reference-Cited by-同舟云学术

Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial

Published:2019-12 Issue:12 Volume:15 Page:e1090-e1098
ISSN:1969-6213
Container-title:EuroIntervention
language:
Short-container-title:EuroIntervention

Author:

Serruys Patrick W.,Tomaniak Mariusz,Chichareon Ply,Modolo Rodrigo,Kogame Norihiro,Takahashi Kuniaki,Chang Chun Chin,Spitzer Ernest,Walsh Simon J.,Adlam David,Hildick-Smith David,Édes István,van de Harst Pim,Krackhardt Florian,Tijssen Jan G.P.,Rademaker-Havinga Tessa,Garg Scot,Steg Philippe Gabriel,Hamm Christian,Jüni Peter,Vranckx Pascal,Onuma Yoshinobu,Verheugt Freek W.A.

Publisher

Europa Digital & Publishing

Subject

Cardiology and Cardiovascular Medicine

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention;Journal of Cardiovascular Development and Disease;2022-10-06

2. Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary intervention: a landmark analysis of the GLOBAL LEADERS trial;EuroIntervention;2022-08

3. Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trial;Catheterization and Cardiovascular Interventions;2022-05-02

4. The impact of kidney function in patients on antithrombotic therapy: a post hoc subgroup analysis focusing on recurrent bleeding events from the AFIRE trial;BMC Medicine;2022-02-25

5. Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Pre‐Specified Analysis of the GLOBAL LEADERS Trial;Journal of the American Heart Association;2021-09-21